menu
    • menu
    [{"orgOrder":0,"company":"Spectral Medical","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Dialco Medical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Dialco Medical","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Dialco Medical"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"}]

    Find Clinical Drug Pipeline Developments & Deals for Polymyxin B Sulfate

    Menu

    Polymyxin B Sulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spectral Medical Provides Tigris Trial Update

                            Details : Toraymyxin (Polymyxin B) is a small molecule drug candidate which is shown to inhibit bacterial respiration. It is being evaluated for the treatment of septic shock.

                            Product Name : Toraymyxin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 04, 2024

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Paradigm Capital

                            Deal Size : $6.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing

                            Details : The proceeds will primarily support Phase III trial for PMX treatment of endotoxemic septic shock, evaluating Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that removes endotoxin.

                            Product Name : Toraymyxin

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Paradigm Capital

                            Deal Size : $6.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Paradigm Capital

                            Deal Size : $8.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Spectral Medical Inc. Announces Closing of C$8.5 Million Convertible Notes Financing

                            Details : The net proceeds from the offering are expected to be primarily used by the company on its late-stage product Toraymyxin (Polymyxin B) for its PMX treatment for endotoxemic septic shock.

                            Product Name : Toraymyxin

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Paradigm Capital

                            Deal Size : $8.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Spectral Medical Extends Exclusive Supply Agreement with Baxter Healthcare

                            Details : Baxter holds exclusive rights to commercialize Toraymyxin (polymyxin B), a therapeutic device removing endotoxins from the bloodstream, guided by Spectral’s Endotoxin Activity Assay.

                            Product Name : Toraymyxin

                            Product Type : Other Small Molecule

                            Upfront Cash : $5.0 million

                            February 21, 2024

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spectral Medical Provides Tigris Trial Update

                            Details : PMX (Toraymyxin™ PMX-20R) is a polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin which can cause sepsis, from the bloodstream.

                            Product Name : Toraymyxin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Paradigm Capital

                            Deal Size : $3.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Spectral Medical Inc. Announces C$5 Million Bought Deal Convertible Note Financing

                            Details : The net proceeds are expected to be primarily used by the Company on its Phase III registration trial (Tigris) for its unique product for the treatment of patients with septic shock, Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that remov...

                            Product Name : Toraymyxin

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 08, 2023

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Paradigm Capital

                            Deal Size : $3.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Spectral Medical

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Dialco Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spectral Medical Provides Update on Tigris Clinical Trial

                            Details : Toraymyxin PMX 20R, is a Polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin in the bloodstream.

                            Product Name : Toraymyxin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 20, 2022

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Dialco Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth